These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10559066)

  • 1. Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients: the long and the short of it!
    Orens JB
    Chest; 1999 Nov; 116(5):1152-3. PubMed ID: 10559066
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
    Cochrane AB
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
    Zamora MR
    Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent?
    Singh N; Yu VL
    Dig Dis Sci; 1998 Jun; 43(6):1190-2. PubMed ID: 9635606
    [No Abstract]   [Full Text] [Related]  

  • 7. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.
    Limaye AP; Raghu G; Koelle DM; Ferrenberg J; Huang ML; Boeckh M
    J Infect Dis; 2002 Jan; 185(1):20-7. PubMed ID: 11756977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
    J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.
    Zamora MR; Davis RD; Leonard C;
    Transplantation; 2005 Jul; 80(2):157-63. PubMed ID: 16041258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
    Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
    Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients.
    Weill D; Zamora MR
    J Heart Lung Transplant; 2000 Aug; 19(8):815-6. PubMed ID: 10967278
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients.
    Mullen GM; Silver MA; Malinowska K; Lawless CE; Lichtenberg RC; Barath PC; O'Keefe PJ; Robinson JA; Yeldandi V
    Transplant Proc; 1998 Dec; 30(8):4110-2. PubMed ID: 9865316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.